Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1176/appi.neuropsych.14010011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Patient Reported Outcome Measure of Side Effects for Patients Taking Calcineurin Inhibitors: The FACIT-CNI-Ntx.
Am J Kidney Dis
January 2025
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, USA; Northwestern University Transplant Outcomes Research Collaborative, Comprehensive Transplant Center, Feinberg School of Medicine, Chicago, IL, USA; Centre for Patient Reported Outcomes Research, Department of Applied Health Sciences, University of Birmingham, Edgbaston, Birmingham, UK.
Rationale & Objective: Valid measures of side effects are important to inform clinical use of calcineurin inhibitors (CNIs). This study sought to develop and establish the content validity of a PRO measure to capture side effects among kidney transplant recipients taking CNIs.
Study Design: Qualitative interviews for concept elicitation and cognitive debriefing.
Tacrolimus- and Mycophenolate-Mediated Toxicity: Clinical Considerations and Options in Management of Post-Transplant Patients.
Curr Issues Mol Biol
December 2024
Department of Anesthesiology, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA 71103, USA.
Tacrolimus and mycophenolate are important immunosuppressive agents used to prevent organ rejection in post-transplant patients. While highly effective, their use is associated with significant toxicity, requiring careful management. Tacrolimus, a calcineurin inhibitor, is linked to nephrotoxicity, neurotoxicity, metabolic disturbances such as diabetes mellitus and dyslipidemia, and cardiovascular complications such as hypertension and arrhythmias.
View Article and Find Full Text PDFSublingual Administration of Tacrolimus is Safe and Provides Similar Drug Exposure to Per-oral Route in Liver Transplant Recipients During Early Postoperative Period-A Large, Retrospective, Observational Study.
J Clin Exp Hepatol
October 2024
Department of Hepato-Pancreato-Biliary Surgery and Liver Transplantation, BLK MAX Super Specialty Hospital, New Delhi, India.
Background/aims: Per-oral (PO) administration of tacrolimus (TAC) results in inadequate trough levels in the early postoperative period in liver-transplant (LT) recipients who undergo Roux-en-Y hepaticojejunostomy for biliary reconstruction. Sublingual administration (SL) of tacrolimus provides an alternative route in such patients.The objectives of this study were to assess the feasibility and safety of SL tacrolimus in adult LT-recipients in the early postoperative period and to compare therapeutic efficacy of SL administration of tacrolimus versus PO route.
View Article and Find Full Text PDFLate-onset tacrolimus-induced encephalopathy in lung transplant recipient: Case report.
Heliyon
November 2024
State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Department of Organ transplantation, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, PR China.
Article Synopsis
- * A case study of a 61-year-old woman showed confusion and muscle stiffness 29 months post-lung transplant, revealing a diagnosis of tacrolimus-induced encephalopathy despite normal drug levels in her blood.
- * After switching her treatment from tacrolimus to cyclosporine, her neurological symptoms improved, indicating that tacrolimus was the cause of her condition, even when drug levels were considered safe.
Impact of Paxlovid on Tacrolimus Concentration in Kidney Transplant Patients: A Retrospective Observational Study.
Transplant Proc
November 2024
Department of Pharmacy, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address:
Kidney transplant recipients, reliant on lifelong immunosuppressive therapy, face potential drug interactions with emerging treatments such as paxlovid. This study aims to provide guidance for safe administration by examining the impact of paxlovid on tacrolimus levels in kidney transplant recipients. Seven kidney transplant patients who received paxlovid between December 2022 and August 2023 were included for retrospective analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!